There's an interesting existing use for DHE that Allergan wouldn't be too happy with - treating chronic headaches or status migrainosus (ongoing continual headache). The current methodology relies on several days of repeated infusions (either in hospital or, in one trial, using visiting nurses). With the MAPP inhaled technology of course this could be a do-it-yourself process. Results were actually pretty good for this difficult-to-treat group.
Here's a sample abstract from Neil Raskin, who was the pioneer in the use of DHE:
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.